Sugi Predict
/ Targets
/ CKS2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to CKS2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| Effect of Silymarin in Metastatic Colorectal Cancer Patients |
PHASE3 | UNKNOWN |
| Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer |
PHASE3 | ACTIVE_NOT_RECRUITING |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) |
PHASE3 | COMPLETED |
| Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
PHASE2 | COMPLETED |
| CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Abemaciclib With or Without Atezolizumab for mCRPC |
PHASE2 | COMPLETED |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Avelumab, Palbociclib and Axitinib in Advanced RCC |
PHASE2 | WITHDRAWN |
| Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 |
PHASE2 | COMPLETED |
| An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. |
PHASE1/PHASE2 | COMPLETED |
| Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC |
PHASE2 | COMPLETED |
| Genetic Testing in Guiding Treatment for Patients With Brain Metastases |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) |
PHASE1/PHASE2 | RECRUITING |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation |
PHASE2 | ACTIVE_NOT_RECRUITING |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy |
PHASE2 | COMPLETED |
| Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer |
PHASE2 | COMPLETED |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Dose-escalation Study of Oral CX-4945 |
PHASE1 | UNKNOWN |
| TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy |
PHASE1 | RECRUITING |
| Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma |
PHASE1 | UNKNOWN |
| Molecular Analysis Of Solid Tumors |
nan | RECRUITING |
| Implementing Patients´ Competence in Oral Breast Cancer Therapy |
nan | UNKNOWN |
| Identification of Novel Targetable Kinases in SR-a GvHD |
nan | COMPLETED |
| Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults |
nan | COMPLETED |
| Tissue Predictors of Abiraterone Benefit |
nan | COMPLETED |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a CKS2 binder may also engage these)